Citius Oncology (CTOR) Accumulated Expenses (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Accumulated Expenses data on file, last reported at $4.1 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 53.42% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 53.42% decrease from a year earlier, with the FY2025 full-year figure at $4.1 million, changed N/A from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.1 million, roughly flat from $4.1 million in the prior quarter.
• Over the last five years, Accumulated Expenses for CTOR reached as high as $8.7 million in Q1 2025 and fell as low as $60000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $3.6 million across 4 years, with a median of $4.1 million in 2025.
• Across the five-year window, Accumulated Expenses surged 10281.02% in 2024 and sank 53.42% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $60000.0 in 2023, then jumped by 10281.02% to $6.2 million in 2024, then tumbled by 34.78% to $4.1 million in 2025, then changed by 0.0% to $4.1 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $4.1 million in Q1 2026, $4.1 million in Q4 2025, and $4.1 million in Q3 2025.